Ranbaxy Denies Being Barred From Germany

In a clarification to the National Stock Exchange (NSE), Ranbaxy has denied reports of being banned in Germany. The pharmaceutical major stated that the regulating authorities in Europe as well as in Australia and Canada have given approvals to the drugs manufactured in the firm’s Dewas plant in Madhya Pradesh.

“The development pertains to only the Company’s cephalosporin injectable unit at Dewas in Madhya Pradesh. The European authorities along with those from Australia and Canada carried out an inspection in June 2014 of all the facilities in Dewas. Well before that time, the Company had decided, to stop producing cephalosporin injectables at Dewas,” said the company in its letter.

In a regular correspondence with the company, the exchange had sought a clarification from the company after a media report stated that Germany had banned certain drugs (anti-biotic) produced in the Dewas facility. The report suggested that the authorities in Germany had also communicated the same to European Medicines Agency.

However, the company begs to differ. “…Since then, the agencies have approved all our facilities for manufacturing Dosage Forms and APIs (Active Pharmaceutical Ingredients) at Dewas including that for oral cephalosporins with the only exception of the cephalosporin injectable unit. We wish to state that Ranbaxy's decision to discontinue manufacture of Cephalosporin injectables would not have a significant impact on the business,” stated the company.

Ranbaxy also asserted that it has all the necessary approvals to produce drugs, which cover other manufacturing units of the company.

Representational Image: Indiatimes.com